INmune Bio
INMB
82 hedge funds and large institutions have $6.09M invested in INmune Bio in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
45% more call options, than puts
Call options by funds: $55K | Put options by funds: $38K
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
11% more funds holding
Funds holding: 74 → 82 (+8)
1.1% more ownership
Funds ownership: 19.12% → 20.23% (+1.1%)
23% less capital invested
Capital invested by funds: $7.93M → $6.09M (-$1.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$356K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$274K |
| 3 |
Goldman Sachs
New York
|
+$250K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$76K |
| 5 |
Jane Street
New York
|
+$39.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$173K |
| 2 |
Morgan Stanley
New York
|
-$111K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$80.5K |
| 4 |
State Street
Boston,
Massachusetts
|
-$80.3K |
| 5 |
JG
Jain Global
New York
|
-$65.6K |
INMB Hedge Fund Activity: Q1 2026 in Review
82 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2026, worth a combined $6.09M — down 23% from $7.93M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INMB positions and 9 closed out — a net gain of 9 holders — while 25 added to existing stakes and 21 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $356K. The largest seller was Dauntless Investment Group, cutting an estimated $173K.
- 82 institutional investors held INmune Bio (INMB) as of Q1 2026, up from 74 in Q4 2025.
- Funds reported $6.09M of INmune Bio stock for Q1 2026, down 23% quarter-over-quarter.
- 18 funds opened new INmune Bio positions in Q1 2026 and 9 closed out, a net change of +9 holders.
- The largest INmune Bio buyer in Q1 2026 was AQR Capital Management, an estimated $356K added.
- The largest INmune Bio seller in Q1 2026 was Dauntless Investment Group, an estimated $173K sold.
Based on aggregated 13F filings for Q1 2026.